Abstract: Objective：To investigate whether C19orf28 has prognostic value for patients with gastric cancer (GC). Methods：Immunohistochemical staining (IHC) was used to detect the expression of C19orf28 in 141 GC tissues and adjacent tissues (5 cm from cancer tissue). Results：The expression of C19orf28 in GC tissues was significantly higher than that in adjacent tissues. There was no significant difference in the clinicopathologic features of patients (n=43) with high expression of C19orf28 and those (n=98) with low expression of C19orf28. The overall survival (OS) of patients with high expression of C19orf28 was significantly shorter than that of patients with low expression of C19orf28 (P=0.000 3). The mean survival time of patients with high expression of C19orf28 (23.40 months) was statistically shorter than that of patients with low expression of C19orf28 (38.35 months, P<0.01). Cox multivariate risk regression model analysis results showed that C19orf28 expression (HR=2.34, P=0.005, 95% CI 1.30-4.21) was an independent predictor of poor prognosis in patients with GC. Conclusions：The expression of C19orf28 protein in GC may be related to the poor prognosis of GC patients, and it has potential application value in predicting the prognosis of GC patients.